NCT06157892 2026-03-17
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen Inc.
Phase 2 Recruiting
Clinical Trials
14 trialsNCT07446452 2026-03-03
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT04879329 2026-01-07
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Seagen Inc.
Phase 2 Recruiting
NCT06178159 2025-10-01
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT07065435 2025-07-15
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06540729 2025-07-08
DAB
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06730373 2024-12-31
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT06749860 2024-12-27
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT06560528 2024-08-19
Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06187506 2024-07-12
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Fudan University
Phase 2 Recruiting
NCT06227156 2024-05-23
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT06389006 2024-05-23
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT06155396 2024-02-28
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT05957757 2023-08-31
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
RenJi Hospital
Phase 2 Recruiting